Other Assets - Additional Information (Detail) (USD $)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2014
|
Jun. 30, 2014
|
Jun. 30, 2013
|
Jun. 30, 2013
Maximum [Member]
|
Jun. 30, 2014
Maximum [Member]
|
Jun. 30, 2014
CeloNova BioSciences, Inc. [Member]
Maximum [Member]
|
Jun. 30, 2014
ThermopeutiX, Inc. [Member]
|
Jun. 30, 2014
ThermopeutiX, Inc. [Member]
Maximum [Member]
|
Mar. 31, 2013
ViaCyte, Inc. [Member]
|
Jun. 30, 2014
ViaCyte, Inc. [Member]
|
Sep. 30, 2006
ViaCyte, Inc. [Member]
|
Jun. 30, 2014
ViaCyte, Inc. [Member]
Maximum [Member]
|
Dec. 31, 2013
Investment In Vessix Vascular, Inc. [Member]
|
Jun. 30, 2014
Investment In Vessix Vascular, Inc. [Member]
|
Sep. 30, 2010
Investment In Vessix Vascular, Inc. [Member]
|
Jun. 30, 2014
Investment In Vessix Vascular, Inc. [Member]
Clinical milestone [Member]
|
Jun. 30, 2014
Investment In Vessix Vascular, Inc. [Member]
Sales milestone [Member]
|
Jun. 30, 2014
Investment In Vessix Vascular, Inc. [Member]
Maximum [Member]
|
|
Schedule of Investments [Line Items] | ||||||||||||||||||
Company's ownership percentage | 2.00% | 20.00% | 1.00% | |||||||||||||||
Impairment loss on investment | $ 1,200,000 | $ 100,000 | $ 5,300,000 | $ 4,700,000 | $ 2,500,000 | $ 2,400,000 | ||||||||||||
Cost method of investment | 500,000 | |||||||||||||||||
Gain on sale of investment | 835,000 | 1,460,000 | 1,200,000 | |||||||||||||||
Milestone payment to be received | 700,000 | 700,000 | ||||||||||||||||
Potential proceeds on achievement of future milestones | 3,400,000 | |||||||||||||||||
Revenue recognized from activity with companies in which it had strategic investment | $ 0 | $ 100,000 | $ 100,000 | $ 100,000 |